Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
3.875
-0.025 (-0.64%)
Jun 12, 2025, 9:45 AM - Market open
Design Therapeutics Employees
Design Therapeutics had 54 employees as of December 31, 2024. The number of employees decreased by 4 or -6.90% compared to the previous year.
Employees
54
Change (1Y)
-4
Growth (1Y)
-6.90%
Revenue / Employee
n/a
Profits / Employee
-$1,040,704
Market Cap
219.98M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54 | -4 | -6.90% |
Dec 31, 2023 | 58 | 0 | - |
Dec 31, 2022 | 58 | 20 | 52.63% |
Dec 31, 2021 | 38 | 23 | 153.33% |
Dec 31, 2020 | 15 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
DSGN News
- 8 days ago - Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - GlobeNewsWire
- 15 days ago - Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - GlobeNewsWire
- 7 weeks ago - Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - GlobeNewsWire
- 2 months ago - Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire